// App-Quantinova.ai

SAT0202 (2018) : Comparison of the bioavailability of a single dose of certolizumab pegol injected by pre-filled syringe or by electro-mechanical auto-injection e-device: a phase 1, open-label, randomised, parallel group, single-centre bioequivalence study

Researchers

Presenter

  • R. Oliver

Principal Investigators

  • B. VanLunen

  • I. Mountian

  • E. Brown

  • D. Tatla

Medical Centers

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma Raleigh NC United States

  • UCB Pharma, Brussels, Belgium

Locations

  • United Kingdom

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Parallel Group

  • Single Center

Phase

  • I

Study Id's

  • NCT02806219

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved